Thursday, January 1, 2026 1/1/2026

Auricular Point Acupressure to Manage Chemotherapy Induced Neuropathy

Award Number: R01CA245054
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/01/2020
PERIOD OF PERFORMANCE END DATE: 05/31/2026

Group Awards By:

View Award Description

Auricular Point Acupressure to Manage Chemotherapy Induced Neuropathy - More than 60% cancer patients experience chemotherapy-induced neuropathy (CIN), a severe side effect of chemotherapy (including platinum drugs, vinca alkaloids, taxanes and/or bortezomib). CIN may cause treatment delays, dose reductions, or discontinuation of therapy which can affect survival rates. With improved cancer treatments and longer survival, the late effects of CIN continue to produce a significant burden in up to 50% of cancer survivors who are suffering from CIN 6 years after treatment, with a 1.8-fold increased risk of falls. CIN continues to cause significant functional disability, negatively impacts quality of life, and significantly demands high health care costs and resource use. We propose to test auricular point acupressure (APA)—a non-invasive and nonpharmacological patient managed strategy—as an innovative solution for CIN. APA is developed from auricular acupuncture, which is an invasive (using needles) and passive treatment (administered by a licensed practitioner). APA is a non-invasive and active treatment for patients with pain. It involves needleless acupuncture-like stimulation of ear points. Small seeds are taped on specific ear points by a skilled provider and patients press on the seeds to stimulate ear points three times daily, three minutes per time, for a total of nine minutes per day to achieve pain relief. APA provides pain relief within 1–2 minutes after ear stimulation and sustains pain relief for one month after a 4-week APA intervention. APA is popular in Taiwan, China, and Europe. Though its use is sparse in the U.S., a limited number of clinical trials have supported APA in pain management. This study will provide vital information to gain a comprehensive understanding of underlying mechanism of APA on CIN and provide strong impetus for including APA as part of CIN management in clinical settings.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2024	UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON	7000 FANNIN ST FL 9	HOUSTON	TX	77030	HARRIS	USA	Cancer Treatment Research	000	5	11/26/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2024	UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON	7000 FANNIN ST FL 9	HOUSTON	TX	77030	HARRIS	USA	Cancer Treatment Research	000	5	4/21/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $793,335 )
2024	2024	UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON	7000 FANNIN ST FL 9	HOUSTON	TX	77030	HARRIS	USA	Cancer Treatment Research	001	5	6/25/2024	SUPPLEMENT FOR EXPANSION	$187,977
2024	2024	UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON	7000 FANNIN ST FL 9	HOUSTON	TX	77030	HARRIS	USA	Cancer Treatment Research	000	5	6/17/2024	NON-COMPETING CONTINUATION	$605,358
														Subtotal = $793,335

Issue Date FY: 2023 ( Subtotal = $854,353 )
2023	2023	UNIVERSITY OF HEALTH SCIENCE CENTER	7000 FANNIN ST	HOUSTON	TX	77030	HARRIS	USA	Cancer Treatment Research	001	4	9/13/2023	SUPPLEMENT FOR EXPANSION	$197,872
2023	2023	UNIVERSITY OF HEALTH SCIENCE CENTER	7000 FANNIN ST	HOUSTON	TX	77030	HARRIS	USA	Cancer Treatment Research	002	4	9/14/2023	SUPPLEMENT FOR EXPANSION	$0
2023	2023	UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON, THE	7000 FANNIN ST	HOUSTON	TX	77030	HARRIS	USA	Cancer Treatment Research	000	4	8/11/2023	NON-COMPETING CONTINUATION	$656,481
														Subtotal = $854,353

Issue Date FY: 2022 ( Subtotal = $1 )
2022	2022	UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON, THE	7000 FANNIN ST	HOUSTON	TX	77030	HARRIS	USA	Cancer Treatment Research	007	3	8/22/2022	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$946,568
2022	2022	UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON, THE	7000 FANNIN ST	HOUSTON	TX	77030	HARRIS	USA	Cancer Treatment Research	001	3	8/10/2022	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$1
2022	2022	UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON, THE	7000 FANNIN ST	HOUSTON	TX	77030	HARRIS	USA	Cancer Treatment Research	004	3	8/18/2022	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$0
2022	2022	UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON, THE	7000 FANNIN ST	HOUSTON	TX	77030	HARRIS	USA	Cancer Treatment Research	002	3	8/11/2022	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	-$1
2022	2022	UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON, THE	7000 FANNIN ST	HOUSTON	TX	77030	HARRIS	USA	Cancer Treatment Research	003	3	8/16/2022	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$1
2022	2021	JOHNS HOPKINS UNIVERSITY, THE	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Cancer Treatment Research	006	2	8/22/2022	NON-COMPETING CONTINUATION	-$669,413
2022	2021	JOHNS HOPKINS UNIVERSITY, THE	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Cancer Treatment Research	000	2	8/10/2022	NON-COMPETING CONTINUATION	$0
2022	2020	JOHNS HOPKINS UNIVERSITY, THE	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Cancer Treatment Research	005	1	8/22/2022	NEW	-$277,155
														Subtotal = $1

Issue Date FY: 2021 ( Subtotal = $669,413 )
2021	2021	JOHNS HOPKINS UNIVERSITY, THE	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Cancer Treatment Research	000	2	6/17/2021	NON-COMPETING CONTINUATION	$669,413
														Subtotal = $669,413

Issue Date FY: 2020 ( Subtotal = $656,091 )
2020	2020	JOHNS HOPKINS UNIVERSITY, THE	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Cancer Treatment Research	000	1	6/29/2020	NEW	$656,091
														Subtotal = $656,091

Grand Total All Awards = $2,973,193

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Auricular Point Acupressure to Manage Chemotherapy Induced Neuropathy

Award Number: R01CA245054

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/01/2020

PERIOD OF PERFORMANCE END DATE: 05/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer